Skip to content

Switching from Wegovy to Zepbound

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

For switching from Wegovy to Zepbound, neither label gives a dose conversion. The Zepbound label states a starting dose of 2.5 mg once weekly for 4 weeks, and both labels say the two shouldn't be used together. Self-pay Zepbound vials cost $299 to $449 a month, compared with $349 for Wegovy 2.4 mg pens.

Source: LillyDirect self-pay

Key takeaways

  • No label turns Wegovy 2.4 mg, or any Wegovy dose, into a Zepbound dose. Your prescriber decides.
  • Zepbound's label starts at 2.5 mg once weekly for 4 weeks and says nothing about earlier treatment.
  • Both labels say not to use the two together. Give your prescriber the date of your last Wegovy shot.
  • Paying cash through LillyDirect? At 7.5 mg and above, refill within 45 days to keep the lower price.
  • On the Medicare GLP-1 Bridge, only the Zepbound KwikPen is covered, and the switch needs a new prior authorization.

What the labels say about switching from Wegovy to Zepbound

The Zepbound label gives one starting dose for everyone: 2.5 mg once weekly. It gives no dose conversion from Wegovy.

The recommended starting dosage of ZEPBOUND for all indications is 2.5 mg injected subcutaneously once weekly for 4 weeks. The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage.
  • The Zepbound label gives no instructions for switching from another GLP-1 medicine; it only gives the starting dose (2.5 mg once weekly).

    FDA label: Revised: 8/2026 (DailyMed version 40)

  • The Wegovy label says using Wegovy tablets or Wegovy injection together with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.

    Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.

    FDA label: Revised: 6/2026 (DailyMed version 19)

  • The Zepbound label says using Zepbound together with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended.

    ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.

    FDA label: Revised: 8/2026 (DailyMed version 40)

Cheapest verified self-pay price, before and after the switch
How you payPer fill
Wegovy 7.2 mgNovoCare self-pay$399
Zepbound 2.5 mgMeasured$348

Try other combinations in the switching planner. Switching is a prescriber decision.

Wegovy and Zepbound are the two weekly injections approved for long-term weight reduction in adults. They’re made by different companies and contain different molecules: semaglutide and tirzepatide. The labels say very little about moving from one to the other.

What do the Wegovy and Zepbound labels say?

Two things, and both are about what not to do.

The Zepbound label says using it with any GLP-1 receptor agonist isn’t recommended. The Wegovy label says using it with any other GLP-1 receptor agonist isn’t recommended. So the labels agree that Zepbound replaces Wegovy. You don’t take both.

Beyond that, the Zepbound label gives no steps for switching from another GLP-1 medicine. The Wegovy label’s switching section only covers its own injection and tablets. Neither document converts 1.7 mg, 2.4 mg or 7.2 mg of Wegovy into a Zepbound dose.

Where does the Zepbound label start?

At 2.5 mg once weekly for 4 weeks, for every approved use. After that, the label raises the dose to 5 mg, and allows more 2.5 mg increases after at least 4 weeks at each step. For weight reduction, the recommended maintenance dose (the dose you stay on) is 5 mg, 10 mg or 15 mg once weekly. The 2.5 mg dose isn’t approved for staying on.

People who reached the top of the Wegovy schedule often ask whether they have to start again at the bottom of Zepbound’s. The label doesn’t mention earlier treatment at all. So the honest answer is that your prescriber decides. This site doesn’t publish a conversion.

What will you pay?

The self-pay prices are:

  • Wegovy now. NovoCare pens are $349 a month from 1 mg through 2.4 mg, and $399 for 7.2 mg.
  • Zepbound vials. LillyDirect charges $299 a month at 2.5 mg, $399 at 5 mg and $449 at 7.5 mg to 15 mg, as long as you buy each refill within 45 days. Miss that window at 10 mg or above and the fill costs $699.
  • Zepbound KwikPen. The same LillyDirect prices apply, $299 to $449.

So your first Zepbound fills can cost less than Wegovy. After that, Zepbound 5 mg costs the same as the Wegovy 7.2 mg pen and more than the lower Wegovy doses, and 7.5 mg and above cost more than any Wegovy pen. If you’re coming from NovoCare, the refill clock is new to you, because NovoCare has no such rule. The Zepbound cost page and the 45-day rule page have the details.

If your commercial insurance covers the drug, each brand’s savings card brings a fill down to as little as $25. The Wegovy card doesn’t work on Zepbound, so sign up for Lilly’s.

Coverage after the switch

Both medicines are approved for weight reduction, so you stay in the same benefit category. You don’t keep the same approval. A plan can prefer one brand, and a formulary (the plan’s list of covered drugs) that lists Wegovy may not list Zepbound, or the other way around. Ask your plan which one it prefers before the prescription is written, and expect a new prior authorization (the plan’s approval before it pays).

Two differences in approved uses matter if your coverage depends on them. Wegovy is approved to lower cardiovascular risk in adults with established cardiovascular disease, and for MASH. Zepbound isn’t. Zepbound is approved for moderate to severe obstructive sleep apnea in adults with obesity. Wegovy isn’t.

On the Medicare GLP-1 Bridge, every Wegovy form is covered, but only the KwikPen form of Zepbound. The switch needs a new prior authorization.

Practical steps

  1. Tell your prescriber the dose and date of your last Wegovy injection, and which side effects you had.
  2. Ask which Zepbound form you’ll get. The vial, single-dose pen and KwikPen are priced and covered differently.
  3. If you take birth control pills, note that the Zepbound label advises a non-oral method, or an added barrier method, for 4 weeks after starting and after each dose increase.
  4. Get the prior authorization filed before your Wegovy supply runs out.
  5. If you’re paying cash, set a reminder for the LillyDirect refill window.

See the reverse move in Zepbound to Wegovy, or try other pairs in the switching planner.

Frequently asked questions

What dose of Zepbound is equivalent to Wegovy 2.4 mg?

No FDA label gives one. Wegovy is semaglutide and Zepbound is tirzepatide, and the Zepbound label has no table matching its doses to Wegovy's. It states a starting dose of 2.5 mg once weekly for 4 weeks, then 5 mg, with later increases in 2.5 mg steps. Your prescriber decides what you're prescribed after Wegovy.

How long should I wait between Wegovy and Zepbound?

Neither label gives a waiting period for this switch. Both are weekly injections, and both labels say using the two together isn't recommended. That leaves the timing of your first Zepbound dose to your prescriber. Give them the date of your last Wegovy injection so they can set it.

Is Zepbound cheaper than Wegovy?

It depends on the dose. Zepbound vials are $299 a month at 2.5 mg and $399 at 5 mg, then $449 at 7.5 mg and above if you refill on time. Wegovy pens are $349 a month at 1 mg to 2.4 mg, and the Wegovy pill is $299 at 25 mg.

Does the Medicare GLP-1 Bridge cover a switch from Wegovy to Zepbound?

It can, with conditions. The Bridge covers Wegovy and the Zepbound KwikPen at a $50 copay, but not Zepbound single-dose pens or vials. An existing approval covers refills and dose changes, but you need a new prior authorization when you switch to a different covered GLP-1. Your prescriber sends it in.

Sources (11)

  1. 1.
    FDA label (DailyMed): Zepbound prescribing information, section 1
    “ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
  2. 2.
    FDA label (DailyMed): Wegovy prescribing information, section 1
    “Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.”
  3. 3.
    FDA label (DailyMed): Zepbound prescribing information, section 2.2
    “The recommended maintenance dosage is 5 mg, 10 mg, or 15 mg, injected subcutaneously once weekly.”
  4. 4.
    FDA label (DailyMed): Zepbound prescribing information, section 2.1
    “The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage.”
  5. 5.
    FDA label (DailyMed): Zepbound prescribing information, section 8.3
    “Use of ZEPBOUND may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation [see Drug Interactions (7.2) and Clinical Pharmacology (12.2, 12.3)].”
  6. 6.
    FDA label (DailyMed): Zepbound prescribing information, section 2.4
    “Administer ZEPBOUND once weekly at any time of day, with or without meals.”
  7. 7.
  8. 8.
  9. 9.
  10. 10.
  11. 11.